Business Standard

Prescription for recovery in FY23 for underperforming pharma sector

Easing pricing pressures, complex generics uptick in the US, steady India/emerging-market growth potential booster shots

Pharmacy
Premium

Photo: Shutterstock

Ram Prasad Sahu Mumbai
The Nifty Pharma Index was the second-worst performer among Nifty sectoral indices over the past year, shedding over 13 per cent in trade. Over a two-year period, its underperformance has grown starker. It is the only index to generate a mid single-digit return (6 per cent), with its closest competitor enriching investors by over 35 per cent.

Pricing pressures in the US market, rising raw material costs, regulatory headwinds, uneven growth in multiple segments in the India market - both in the formulations and active pharmaceutical (pharma) ingredient segments - were some of the reasons investors kept their distance from

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 26 2022 | 6:10 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com